 |
Photo = GC Holdings |
[Alpha Biz= Paul Lee] GC Holdings has acquired the entire stake in GC Wellbeing from GC Biopharma, signaling potential shifts in the group’s governance structure.
According to a regulatory filing on April 1, GC Biopharma agreed to sell 3.92 million shares of GC Wellbeing—representing a 22.1% stake—to its parent company, GC Holdings. The transaction is valued at approximately KRW 50.5 billion in cash.
GC Holdings stated that the acquisition aims to enhance corporate value and reorganize its business portfolio. Meanwhile, GC Biopharma explained that the divestment is intended to improve its financial structure and secure investment capacity for future growth.
GC Wellbeing has emerged as one of the group’s key subsidiaries, expanding beyond its core offerings—such as placenta-based injections, vitamin therapies, and health supplements—into the fast-growing aesthetics and medical beauty sector.
The company has been actively strengthening its portfolio, including a KRW 40 billion acquisition of botulinum toxin developer Inibio last year. More recently, it launched “Giselle Rebonne,” an extracellular matrix (ECM)-based skin booster, reflecting its push into next-generation aesthetic medical products.
The transaction has also drawn attention as it may indicate changes in the group’s long-standing co-management structure between family members, although further developments remain to be seen.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
